Danielle M. Marra, MS, MBA
Danielle adds value to Defined Health through her contributions to projects focused on opportunity assessments, therapeutic area growth strategy, identification and evaluation of partnering opportunities, and asset valuation. Her experience spans the therapeutic landscape but includes a specific focus on the anti-infective space, including antibiotics, antivirals, and anti-fungals.
Prior to joining Defined Health in 2011, Danielle was a Scientist in the Bioanalytical Development group at an emerging pharmaceutical company in New Jersey where she was responsible for the design, development, and validation of a number of immuno- and cell-based assays for use in preclinical and early phase clinical studies for metabolic and autoimmune bone diseases. Danielle was also involved in performing competitive intelligence for the Business Development team to identify potential partners for licensing, as well as competitors in the peptide therapeutic space.
Danielle received a Masters Degree in Cell and Developmental Biology and an MBA with concentrations in Pharmaceutical Management and Marketing from Rutgers University. Her Masters research focused on the NAD-dependent deacetylase, sirtuin-1, and its activity in colon, breast, and pancreatic cancer. She holds a B.S. in Biology from The College of New Jersey.